TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
The EHE Foundation Welcomes Kristianne Oristian, PhD, as Director of Research & Engagement
The EHE Foundation is proud to announce the appointment of Kristianne (“Kristi”) Oristian, PhD, as our new Director of Research & Engagement. In this role, Kristi will work closely with Executive Director Denise Robinson, who previously led both organizational and research strategy, to advance the Foundation’s mission and strengthen our growing impact in the global […]
Advancing EHE Research on the Global Stage: Highlights from CTOS 2025
The EHE Foundation had the privilege of attending the CTOS 2025 Annual Meeting, held November 12-15, in Boca Raton, Florida. The Connective Tissue Oncology Society (CTOS) is a global, professional medical organization of clinician-scientists, translational researchers, and patient advocates united by a single goal: advancing treatment of sarcomas. For the EHE community, this annual gathering […]
The Pledge: Edition 42, Q3 – July-September, 2025
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of the online EHE newsletter, The Pledge.
EHE Stabilization with Sirolimus: Results From POEM, a Prospective Multicentric Observational Study
Drs. Claudia Giani, Anna Maria Frezza, Silvia Stacchiotti, and colleagues from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, and Royal Marsden Hospital, London, UK, presented results from POEM: a prospective observational study on Epithelioid Haemangioendothelioma at ESMO Congress 2025. The data presented included 57 consecutive molecularly confirmed EHE patients who entered the study, […]
Prepare for Progress: Genomic Profiling to Inform Treatment Development and Care Planning
Join the EHE Foundation for a conversation about genomic profiling — an important tool that can help guide treatment decisions, support and inform clinical trials, and pave a path to progress in EHE research. Dr. James L. Chen, a medical oncologist specializing in the diagnosis and treatment of sarcomas at The Ohio State University James Cancer […]
Hanna Lab at Purdue University: ‘When cells in the body stop following the rules, cancer can take hold.’
You met Jason Hanna, PhD, at the 2025 EHE Global Patient Conference, where he highlighted work his lab is undertaking in EHE. We are thrilled to share a recent publication in Molecular Oncology from the Hanna Lab at Purdue University, highlighting their findings from a study focused on the YAP1-TFE3 subtype of EHE. The YAP1-TFE3 […]
Science Saturday: EHE Research Progress & Momentum
Join the EHE Foundation for a special Science Saturday on Rare Disease Day, February 28, 2026, 11:00 am – 12:30 pm ET. This virtual event is designed for anyone affected by EHE who wants an up-to-date view of the EHE research landscape. This free, interactive presentation will highlight Foundation-led research, global scientific advances, and the […]
Reflecting on 2025 and Looking Ahead With Purpose
For the global EHE community, 2025 brought challenges, resilience, and momentum. Grounded in connection and a shared commitment to progress in EHE, we look back with emotion, appreciation, and gratitude, and in 2026, we look forward with determination and hope.
Translating molecular mechanisms of EHE to improve patient outcomes
Scientists know that most EHE tumors are caused by specific genetic changes called gene fusions. In most people with EHE, two genes, WWTR1 and CAMTA1, are abnormally fused. In a smaller number of cases, a different fusion involving YAP1 and TFE3 is present. In a recent review published in Critical Reviews in Oncology/Hematology, the authors […]